0001104659-24-062054.txt : 20240515 0001104659-24-062054.hdr.sgml : 20240515 20240515171905 ACCESSION NUMBER: 0001104659-24-062054 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240515 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240515 DATE AS OF CHANGE: 20240515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Outlook Therapeutics, Inc. CENTRAL INDEX KEY: 0001649989 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 383982704 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37759 FILM NUMBER: 24952605 BUSINESS ADDRESS: STREET 1: 111 S. WOOD AVENUE STREET 2: UNIT #100 CITY: ISELIN STATE: NJ ZIP: 08830 BUSINESS PHONE: 6096193990 MAIL ADDRESS: STREET 1: 111 S. WOOD AVENUE STREET 2: UNIT #100 CITY: ISELIN STATE: NJ ZIP: 08830 FORMER COMPANY: FORMER CONFORMED NAME: Oncobiologics, Inc. DATE OF NAME CHANGE: 20150804 8-K 1 tm2414392d1_8k.htm FORM 8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 15, 2024

Outlook Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-37759	38-3982704
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

111 S. Wood Avenue, Unit #100

Iselin, New Jersey

08830

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code: (609) 619-3990

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock		OTLK		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02

Results of Operations and Financial Condition

On May 15, 2024, Outlook Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for its second fiscal quarter ended March 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Item 9.01

Financial Statements and Exhibits

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release dated May 15, 2024
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Outlook Therapeutics, Inc.

Date: May 15, 2024	By:	/s/ Lawrence A. Kenyon
		Lawrence A. Kenyon
		Chief Financial Officer

EX-99.1 2 tm2414392d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

Outlook Therapeutics^® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update

·

Positive opinion received from Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for ONS-5010/LYTENAVA^™ (bevacizumab gamma)

·

United Kingdom (UK) Marketing Authorization Application (MAA) submitted

·

NORSE EIGHT fully underway in the US; Topline readout expected in Q4 CY2024

·

Resubmission of the ONS-5010 Biologics License Application (BLA) planned by the end of CY2024

·

Company to host inaugural quarterly update conference call and webcast on Thursday, May 16^th at 8:30 AM ET

ISELIN, N.J., May 15, 2024 — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve regulatory approval for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of retinal diseases, today announced financial results for the second quarter of fiscal year 2024 and provided a corporate update. As previously announced, the Company will host its inaugural quarterly conference call and live audio webcast, on Thursday, May 16, 2024, at 8:30 AM ET (details below).

“We are extremely pleased with our corporate, clinical, and regulatory progress. On the regulatory front, we continue to drive toward anticipated marketing authorization of ONS-5010 in the EU and have also submitted our marketing application for authorization in the UK. In the US, we are executing on our NORSE EIGHT clinical trial and advancing toward a topline data readout expected in the fourth quarter of calendar year 2024. On the financial front, assuming full exercise of the warrants issued in our recent private placement transactions, we believe we now have access to sufficient capital to take ONS-5010 through potential FDA approval and funding of the commercial launch,” commented Russell Trenary, President and Chief Executive Officer of Outlook Therapeutics. “We remain steadfast in our mission to enhance the standard of care in the retinal anti-VEGF space. On behalf of the entire team, I would like to thank all our partners and stakeholders for their continued support and look forward to what we believe will be an exciting remainder of the year for Outlook Therapeutics.”

Lawrence Kenyon, Chief Financial Officer of Outlook Therapeutics, added, “Our adjusted financial results for the quarter met our expectations as we initiated the NORSE EIGHT clinical trial and began enrolling patients. We believe we are well positioned financially to continue executing on NORSE EIGHT enrollment, resubmission of the ONS-5010 BLA by the end of calendar 2024, and launch of ONS 5010 in 2025, if approved.”

Upcoming Anticipated Milestones

·

MAA decision in the European Union (EU) for ONS-5010 anticipated in Q2 CY2024;

·

Full enrollment of NORSE EIGHT clinical trial in the US expected in Q3 CY2024;

·

Topline readout of NORSE EIGHT clinical trial planned in Q4 CY2024;

·

Resubmission of the ONS-5010 BLA targeted for the end of CY2024;

·

Planning underway for potential commercial launches in the EU and UK to begin in first quarter of CY2025; and

·

Potential for US FDA approval of ONS-5010 in 2025.

ONS-5010 / LYTENAVA^™ (bevacizumab-vikg) Regulatory Update

As previously announced, following Type A meetings with the FDA in Q4 CY2023, the FDA informed Outlook Therapeutics that it can conduct a non-inferiority study evaluating ONS-5010 versus ranibizumab in a 3-month study of treatment naïve patients with a primary efficacy endpoint at 2 months (NORSE EIGHT). In January 2024, Outlook Therapeutics announced that it received written agreement on the NORSE EIGHT trial protocol and statistical analysis plan from the FDA under a SPA for NORSE EIGHT. The SPA also confirms in writing that if the NORSE EIGHT trial is successful, it would satisfy the FDA’s requirement for a second adequate and well-controlled clinical trial to fully address the clinical deficiency identified in the Complete Response Letter (CRL). In addition, through a Type A meeting and additional interactions, Outlook Therapeutics has identified the approaches needed to resolve the Chemistry, Manufacturing and Controls (CMC) comments in the CRL. Outlook Therapeutics has scheduled a series of Type C and Type D meetings with the FDA to address the open CMC items in the CRL and expects to resolve these comments prior to the expected completion of NORSE EIGHT.

NORSE EIGHT is a randomized, controlled, parallel-group, masked, non-inferiority study of approximately 400 newly diagnosed, wet age-related macular degeneration (wet AMD) subjects randomized in a 1:1 ratio to receive 1.25 mg ONS-5010 or 0.5 mg ranibizumab intravitreal injections. Subjects will receive injections at Day 0 (randomization), Week 4, and Week 8 visits. The primary endpoint is mean change in BCVA from baseline to week 8. Currently, over 30% of the required subjects have been enrolled in the study. Outlook Therapeutics continues to plan NORSE EIGHT enrollment completion in Q3 CY2024, with topline results expected to be reported, and the planned resubmission of the ONS-5010 BLA to occur, by the end of calendar year 2024.

In March 2024, the CHMP issued a positive opinion concerning the EU Marketing Authorization Application (MAA) of ONS-5010/LYTENAVA^™ (bevacizumab gamma), an investigational ophthalmic formulation of bevacizumab for the treatment of wet AMD in the EU. The CHMP positive opinion was based on results from Outlook Therapeutics’ wet AMD clinical program for ONS-5010, which consists of three completed registration clinical trials - NORSE ONE, NORSE TWO and NORSE THREE, as well as studies and peer reviewed literature substituting or supporting certain tests and studies.

This positive opinion supports the grant of marketing authorization by the European Commission for Outlook Therapeutics’ application for ONS-5010 in the EU. The European Commission is expected to make a decision on approval within approximately 67 days following the CHMP opinion. The decision will apply automatically in all 27 EU Member States, and, within 30 days, also to Iceland, Norway and Liechtenstein. If approved, an initial ten years of market exclusivity in the EU is expected for ONS-5010/LYTENAVA^™.

Additionally, the Company recently announced the submission of its MAA to the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK seeking authorization of ONS-5010/LYTENAVA^™ (bevacizumab gamma) for the treatment of wet AMD. The submission was completed under the new International Recognition Procedure (IRP), which allows the MHRA to rely on a positive opinion by the CHMP concerning an application for grant of marketing authorization for the same product in the EU. The IRP is available for new UK MAAs of a medicinal product (having the same qualitative and quantitative composition, and the same pharmaceutical form) that has previously been authorized by a Reference Regulator (RR). In this case this is the EMA.

If ONS-5010/LYTENAVA^™ (bevacizumab-vikg or bevacizumab gamma) is approved, Outlook Therapeutics expects to commercialize it as the first and only European Commission, MHRA or FDA approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the EU, UK, and United States. Authorization may also be sought in other European markets, Japan, and elsewhere. If approved, Outlook Therapeutics plans to commercialize ONS-5010/LYTENAVA^™ (bevacizumab-vikg) directly in the US and is assessing both direct commercialization and partnering for ONS-5010/LYTENAVA^™ (bevacizumab gamma) in Europe and other regions outside of the US.

Financial Highlights for the Fiscal Second Quarter Ended March 31, 2024

For the fiscal second quarter ended March 31, 2024, Outlook Therapeutics reported a net loss attributable to common stockholders of $114.3 million, or $8.01 per basic and diluted share, compared to a net loss attributable to common stockholders of $6.7 million, or $0.52 per basic and diluted share, for the same period last year. For the fiscal second quarter ended March 31, 2024, Outlook Therapeutics also reported an adjusted net loss attributable to common stockholders¹ of $22.1 million, or $1.55 per basic and diluted share, as compared to an adjusted net loss attributable to common stockholders of $6.7 million, or $0.52 per basic and diluted share, for fiscal second quarter 2023.

Adjusted net loss attributable to common stockholders for the fiscal second quarter ended March 31, 2024 includes $34.1 million of warrant related expenses, $49.6 million of increase in fair value of warrant liability and $8.5 million of increase in fair value of convertible promissory notes. Adjusted net loss attributable to common stockholders was not materially different than net loss attributable to common stockholders for the fiscal second quarter ended March 31, 2023.

¹ Adjusted net loss attributable to common stockholders and adjusted net loss attributable to common stockholders per share of common stock – basic and diluted are non-U.S. GAAP financial measures. See “Non-GAAP Financial Measures” below.

In March and April 2024, the Company closed its previously announced private placements of common stock and accompanying warrants. In addition to the upfront gross proceeds of $65 million, the Company has the potential to receive additional gross proceeds of up to $107 million upon the full cash exercise of the warrants issued in the private placements, before deducting placement agent fees and offering expenses.

As of March 31, 2024, Outlook Therapeutics had cash and cash equivalents of $47.2 million.

Conference Call and Webcast

Outlook Therapeutics management will host its inaugural quarterly conference call and live audio webcast for investors, analysts, and other interested parties on Thursday, May 16, 2024 at 8:30 AM ET.

Interested participants and investors may access the conference call by dialing (877) 407-8291 (domestic) or (201) 689-8345 (international) and referencing the Outlook Therapeutics Conference Call. The live webcast will be accessible on the Events page of the Investors section of the Outlook Therapeutics website, outlooktherapeutics.com, and will be archived for 90 days.

About ONS-5010 / LYTENAVA^™ (bevacizumab-vikg, bevacizumab gamma)

ONS-5010/LYTENAVA^™ is an investigational ophthalmic formulation of bevacizumab under development as an intravitreal injection for the treatment of wet AMD and other retinal diseases. Because no FDA or European Commission approved ophthalmic formulations of bevacizumab are currently available, clinicians wishing to treat retinal patients with bevacizumab have had to use repackaged IV bevacizumab authorized for a different therapeutic indication and provided by compounding pharmacies—products that have known risks of contamination and inconsistent potency and availability. If approved, ONS-5010/LYTENAVA^™ would provide an authorized option for physicians to treat wet AMD in the United States, EU and the UK.

Bevacizumab-vikg (bevacizumab gamma in the EU and UK) is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. Following intravitreal injection, the binding of bevacizumab to VEGF prevents the interaction of VEGF with its receptors on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation in the retina.

About Outlook Therapeutics, Inc.

Outlook Therapeutics is a biopharmaceutical company working to achieve FDA, European Commission and MHRA approval for the launch of ONS-5010/LYTENAVA^™ (bevacizumab-vikg or bevacizumab gamma) as the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010/Lytenava™ is approved, Outlook Therapeutics expects to commercialize it as the first and only European Commission, MHRA or FDA approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, EU, and UK. Authorization may also be sought in other European markets, Japan, and other markets. As part of the Outlook Therapeutics multi-year commercial planning process, Outlook Therapeutics and Cencora have entered into a strategic commercialization agreement to expand Outlook Therapeutics’ reach for connecting to retina specialists and their patients. Cencora will provide third-party logistics (3PL) services and distribution, as well as pharmacovigilance services and other services in the United States, EU and UK.

Non-GAAP Financial Measures

Outlook Therapeutics prepares its consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP) and pursuant to accounting requirements of the Securities and Exchange Commission (SEC). In an effort to provide investors with additional information regarding the results and to provide a meaningful period-over-period comparison of Outlook Therapeutics’ financial performance, Outlook Therapeutics sometimes uses non-U.S. GAAP financial measures (NGFM) as defined by the SEC. In this press release, Outlook Therapeutics uses “adjusted net loss attributable to common stockholders,” which is defined as net loss attributable to common stockholders excluding warrant related expenses (i.e., the excess of the fair value of the warrants upon issuance over the proceeds of the private placement that closed on March 18, 2024) and changes in fair value of warrants and convertible promissory notes, as well as “adjusted net loss attributable to common stockholders per share of common stock – basic and diluted,” which is defined as net loss attributable to common stockholders per share of common stock – basic and diluted excluding warrant related expenses and changes in fair value of warrants and convertible promissory notes. Management uses these NGFMs because they adjust for certain non-cash items that impact financial results but not cash flows and that management believes are not related to its core business. Management uses these NGFMs to evaluate Outlook Therapeutics financial performance against internal budgets and targets. Management believes that these NGFMs are useful for evaluating Outlook Therapeutics’ core operating results and facilitating comparison across reporting periods. Outlook Therapeutics believes these NGFMs should be considered in addition to, and not in lieu of, GAAP financial measures. Outlook Therapeutics’ NGFMs may be different from the same NGFMs used by other companies. Reconciliations to the closest U.S. GAAP financial measures are provided in the tables below.

Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “continue,” “expect,” “may,” “plan,” “potential,” “target,” “will,” or “would” the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. These include, among others, expectations concerning decisions of regulatory bodies, including the European Commission, the MHRA and the FDA, and the timing thereof, expectations concerning Outlook Therapeutics’ ability to remediate or otherwise resolve deficiencies identified in the CRL issued by the FDA, including with respect to an additional clinical trial and CMC issues, expectations concerning NORSE EIGHT enrollment, the timing for completion of NORSE EIGHT and resubmission of the BLA for ONS-5010, the expected proceeds from the full exercise of warrants issued in recent private placement transactions, the sufficiency of Outlook Therapeutics’ resources, including funds from the full exercise of the warrants, to fund its operations through various milestones, ONS-5010’s potential as the first and only European Commission, MHRA or FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the EU, UK, and United States, plans for potential commercial launch of ONS-5010, expectations concerning the relationship with Cencora and the benefits and potential expansion thereof, and other statements that are not historical fact. Although Outlook Therapeutics believes that it has a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting Outlook Therapeutics and are subject to risks, uncertainties and factors relating to its operations and business environment, all of which are difficult to predict and many of which are beyond its control. These risk factors include those risks associated with developing pharmaceutical product candidates, risks of conducting clinical trials and risks in obtaining necessary regulatory approvals, the content and timing of decisions by the European Commission, MHRA and FDA, as well as those risks detailed in Outlook Therapeutics’ filings with the Securities and Exchange Commission (the SEC), including the Annual Report on Form 10-K for the fiscal year ended September 30, 2023, filed with the SEC on December 22, 2023, and future quarterly reports Outlook Therapeutics files with the SEC, which include uncertainty of market conditions and future impacts related to macroeconomic factors, including as a result of the ongoing overseas conflicts, high interest rates, inflation and potential future bank failures on the global business environment. These risks may cause actual results to differ materially from those expressed or implied by forward-looking statements in this press release. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Outlook Therapeutics does not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.

Investor Inquiries:

Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 833.475.8247
OTLK@jtcir.com

Outlook Therapeutics, Inc.
Consolidated Statements of Operations
(Amounts in thousands, except per share data)

	Three months ended March 31,						Six months ended March 31,
	2024			2023			2024			2023
Operating expenses:
Research and development	$	13,509		$	545		$	18,038		$	10,407
General and administrative		5,431			6,293			11,225			12,119
		18,940			6,838			29,263			22,526
Loss from operations		(18,940	)		(6,838	)		(29,263	)		(22,526	)
Income on equity method investment		30			17			28			(5	)
Interest (income) expense, net		3,084			(188	)		2,895			2,261
Loss on extinguishment of debt		—			—			—			578
Change in fair value of promissory notes		8,519			3			9,512			3
Warrant related expenses		34,098			—			34,098			—
Change in fair value of warrant liability		49,615			(19	)		49,668			(49	)
Loss before income taxes		(114,286	)		(6,651	)		(125,464	)		(25,314	)
Income tax expense		3			3			3			3
Net loss attributable to common stockholders	$	(114,289	)	$	(6,654	)	$	(125,467	)	$	(25,317	)

Per share information:
Net loss per share of common stock, basic and diluted	$	(8.01	)	$	(0.52	)	$	(9.20	)	$	(2.09	)
Weighted average shares outstanding, basic and diluted		14,270			12,833			13,638			12,094

Consolidated Balance Sheet Data
(Amounts in thousands)

	March 31, 2024			September 30, 2023
Cash and cash equivalents	$	47,229		$	23,392
Total assets	$	59,029		$	32,301
Current liabilities	$	54,080		$	46,732
Total stockholders' deficit	$	(134,236	)	$	(14,438	)

Reconciliation Between Reported Net Loss (GAAP) and Adjusted Net Loss (Non-GAAP), in each case
Attributable to Common Stockholders
(Amounts in thousands, except per share data)

	Three months ended March 31,						Six months ended March 31,
	2024			2023			2024			2023
Net loss attributable to common stockholders, as reported (GAAP)	$	(114,289	)	$	(6,654	)	$	(125,467	)	$	(25,317	)
Adjustments for reconciled items:
Warrant related expenses		34,098			—			34,098			—
Change in fair value of warrant liability		49,615			(19	)		49,668			(49	)
Change in fair value of promissory notes		8,519			3			9,512			3
Adjusted net loss attributable to common stockholders (non-GAAP)	$	(22,057	)	$	(6,670	)	$	(32,189	)	$	(25,363	)

Net loss attributable to common stockholders per share of	$	(8.01	)	$	(0.52	)	$	(9.20	)	$	(2.09	)
common stock - basic and diluted, as reported (GAAP)
Adjustments for reconciled items:
Warrant related expenses		2.39			—			2.50			—
Change in fair value of warrant liability		3.48			—			3.64			(0.01	)
Change in fair value of promissory notes		0.59			—			0.70			—
Adjusted net loss attributable to common stockholders
per share of common stock - basic and diluted (non-GAAP)	$	(1.55	)	$	(0.52	)	$	(2.36	)	$	(2.10	)

EX-101.SCH 3 otlk-20240515.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 otlk-20240515_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 otlk-20240515_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2414392d1_ex99-1img01.jpg GRAPHIC begin 644 tm2414392d1_ex99-1img01.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT

Cover	May 15, 2024
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	May 15, 2024
Entity File Number	001-37759
Entity Registrant Name	Outlook Therapeutics, Inc.
Entity Central Index Key	0001649989
Entity Tax Identification Number	38-3982704
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	111 S. Wood Avenue
Entity Address, Address Line Two	Unit #100
Entity Address, City or Town	Iselin
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08830
City Area Code	609
Local Phone Number	619-3990
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common stock
Trading Symbol	OTLK
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://outlooktherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports otlk-20240515.xsd otlk-20240515_lab.xml otlk-20240515_pre.xml tm2414392d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2414392d1_8k.htm": { "nsprefix": "otlk", "nsuri": "http://outlooktherapeutics.com/20240515", "dts": { "schema": { "local": [ "otlk-20240515.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "otlk-20240515_lab.xml" ] }, "presentationLink": { "local": [ "otlk-20240515_pre.xml" ] }, "inline": { "local": [ "tm2414392d1_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://outlooktherapeutics.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-05-15", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2414392d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-05-15", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2414392d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001104659-24-062054-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-062054-xbrl.zip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end XML 18 tm2414392d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001649989 2024-05-15 2024-05-15 iso4217:USD shares iso4217:USD shares false 0001649989 8-K 2024-05-15 Outlook Therapeutics, Inc. DE 001-37759 38-3982704 111 S. Wood Avenue Unit #100 Iselin NJ 08830 609 619-3990 false false false false Common stock OTLK NASDAQ false